Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sets New 1-Year High – Should You Buy?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $49.0282 and last traded at $49.0282, with a volume of 250 shares. The stock had previously closed at $47.4750.

Wall Street Analyst Weigh In

Several equities analysts recently commented on BIOVF shares. HC Wainwright began coverage on shares of Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They set a “buy” rating for the company. Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Finally, Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, May 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.47 and a current ratio of 0.70. The firm has a market cap of $17.45 billion, a PE ratio of 163.43 and a beta of 0.35. The stock has a fifty day moving average price of $47.71 and a 200-day moving average price of $41.67.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.38 by $0.07. The firm had revenue of $755.76 million for the quarter, compared to analyst estimates of $749.76 million. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 16.66%. Research analysts expect that Swedish Orphan Biovitrum will post 2.22 EPS for the current year.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.